Seattle Cancer Care Alliance

Only a decade ago, many in oncology considered chimeric antigen receptor T-cell therapy too fringe for real-world use.

NEW ORLEANS — A novel chimeric antigen receptor T-cell therapy conferred a 78% complete response rate in patients with heavily pretreated T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, study results showed.

CHICAGO — During the ASCO Annual Meeting, Healio honored our inaugural Healio Disruptive Innovators in hematology/oncology.

Kathleen Shannon Dorcy, PhD, RN, FAAN, received this year’s Connie Henke Yarbro Excellence in Cancer Nursing Mentorship Award.

The Fred Hutch/University of Washington Cancer Consortium has announced new leadership.

Christopher Li, MD, PhD, has been named the first associate director of diversity, equity and inclusion for the Fred Hutch/University of Washington Cancer Consortium.

Of the known racial disparities in cancer incidence and mortality, the disproportionate burden of prostate cancer among Black men remains one of the most pronounced.

Oncologists are in a critical position to provide potentially life-saving information about the COVID-19 vaccine to their patients with cancer, experts said.

An off-the-shelf, virus-specific T-cell therapy demonstrated proof of concept to enter a clinical trial for the treatment of severe COVID-19 infection, according to study results presented at the virtual ASH Annual Meeting and Exposition.

Julie Gralow, MD, is a well-respected and internationally renowned breast oncologist. In this episode, Gralow discusses her journey in oncology, the ASCO Global Oncology Task Force and the importance of finding your own way in medicine.